-transparent.png){kind=logo}
We studied the transfer factor (TF) with regard to in vivo and in vitro restoration of cell mediated immunity (CMI) in lung cancer patients. Twenty-eight lung cancer patients who had undergone resection were the recipients and 30 household contact family members with a positive reactivity to lung cancer extract were the donors of TF. Immunologic status was evaluated by delayed type cutaneous hypersensitivity (DTH), peripheral T lymphocyte number, PHA lymphocyte blastogenesis, serum blocking activity (SBA) and leucocyte adherence inhibition (LAI) test. When TF was administered twice subcutaneously to the patients, there was a statistically significant restoration or augmentation of DTH, PHA lymphocyte blastogenesis and abrogation of SBA, particularly in patients with suppressed CMI. These results suggest that it was the TF obtained from relatives of lung cancer patients with positive reactivity to tumor associated antigens restored or augmented tumor specific and nonspecific CMI in these lung cancer patients.
T Fujisawa, and
Y Yamaguchi, and
H Kimura
January 1976,
Giornale di clinica medica,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
April 1974,
Cellular immunology,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
January 1975,
Birth defects original article series,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
January 1979,
Folia medica Cracoviensia,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
July 1976,
British medical journal,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
March 1973,
Cancer chemotherapy reports. Part 3,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
November 1979,
Cellular immunology,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
January 1996,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
June 1980,
Hansenologia internationalis,
T Fujisawa, and
Y Yamaguchi, and
H Kimura
November 1973,
La Revue du praticien,
